Fidelity Investments
IRD

Fidelity Investments’s Opus Genetics IRD Stock Holding History

Fidelity Investments’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$584 Buy
142
+134
+1,675% +$625 ﹤0.01% 5300
2026
Q1 		$36 Buy
+8
New +$28 ﹤0.01% 5316
2025
Q1 		– Sell
-1
Closed -$1 – 5762
2024
Q4 		$1 Buy
+1
New +$1 ﹤0.01% 5518
2023
Q3 		– Sell
-100
Closed -$434 – 5561
2023
Q2 		$434 Buy
+100
New +$475 ﹤0.01% 4830

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fidelity Investments's IRD Position: Q2 2026 in Review

Fidelity Investments increased its Opus Genetics (IRD) stake by 1,675% in Q2 2026, buying an estimated $625 and bringing the position to 142 shares worth $584. The position accounts for ﹤0.01% of the portfolio, ranked #5300.

Fidelity Investments first reported a position in IRD in Q2 2023 and has held it in 4 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Fidelity Investments held 142 shares of Opus Genetics worth $584 as of Q2 2026.
  • Fidelity Investments bought 134 Opus Genetics shares in Q2 2026, an estimated $625.
  • Opus Genetics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5300 holding.
  • Fidelity Investments first reported a position in Opus Genetics in Q2 2023 and has held it in 4 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.